Boehringer Ingelheim initiates three Phase III clinical trials aimed at precision oncology in cancer types with limited treatment options, according to company materials shared by multiple outlets. The studies include DAREON®-Lung-1 and DAREON®-NEC-1, which evaluate obrixtamig, an “IgG-like” bispecific T-cell engager designed to target DLL3. These trials use a biomarker-informed approach intended to help identify eligible patients and guide treatment decisions. DAREON®-Lung-1 focuses on small cell lung cancer (SCLC), while DAREON®-NEC-1 targets extrapulmonary neuroendocrine carcinoma (epNEC). A third study, Beamion LUNG-3, investigates zongertinib in a lung cancer setting. The announcements frame the program as part of Boehringer Ingelheim’s effort to advance targeted therapies for aggressive cancers where existing options are limited. The sources do not provide additional trial endpoints, locations, or enrollment figures in the text provided.
Boehringer Ingelheim starts three Phase III trials for hard-to-treat cancers
Boehringer Ingelheim initiates three Phase III clinical trials aimed at precision oncology in cancer types with limited treatment options, according to company materials shared by multiple outlets. Th...
- Boehringer Ingelheim starts three Phase III trials in oncology.
- DAREON®-Lung-1 studies obrixtamig in small cell lung cancer (SCLC) using a DLL3 biomarker-informed approach.
- DAREON®-NEC-1 studies obrixtamig in extrapulmonary neuroendocrine carcinoma (epNEC) using DLL3 biomarker-informed selection.
- Obrixtamig is described as an “IgG-like” bispecific T-cell engager targeting DLL3.
- Beamion LUNG-3 evaluates zongertinib in a lung cancer study.
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig, Boehringer's immunoglobin G (IgG)-like bispecific T-cell engager, as a DLL3...
19 hours agoBoehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)1,2 Beamion LUNG-3 will explore zongertinib […]
23 hours ago
Hantavirus cruise travellers released from Perth quarantine after negative tests
Six travellers affected by a hantavirus outbreak linked to an earlier cruise are scheduled to leave a quarantine facilit...
Definium shares jump after LSD-based depression drug reports late-stage trial success
Definium Therapeutics’ shares rise sharply Monday after the company reports that its LSD-based experimental depression t...
Last hantavirus cruise ship passengers leave Nebraska quarantine facility
The last eight American passengers who were exposed to an unusual hantavirus during a cruise ship outbreak leave a speci...